Core Viewpoint - The stock of药捷安康-B (02617) has surged over 60% in early trading, reaching a high of 679.5 HKD, with a cumulative increase of nearly 10 times since its entry into the market [1] Group 1: Stock Performance - As of the latest update, the stock is up 50.6%, trading at 625.5 HKD, with a transaction volume of 1.177 billion HKD and a market capitalization that briefly surpassed 250 billion HKD [1] - Following its inclusion in the Hong Kong Stock Connect program effective September 8, there has been a continuous increase in investment from northbound funds, with purchases of 180 million HKD and 142 million HKD on September 12 and September 15, respectively [1] Group 2: Company Overview -药捷安康 focuses on the discovery and development of small molecule innovative therapies for oncology, inflammation, and cardiovascular metabolic diseases [1] - As of June 30, 2025, the company has six clinical-stage candidate products and multiple preclinical-stage candidates in its pipeline [1] Group 3: Financial Performance - The company reported no revenue from its main business in the first half of the year, with other income declining from 10.4 million HKD in the first half of 2024 to 3.6 million HKD, a decrease of 65.1% [1] - The core product,替恩戈替尼 (TT-00420), has recently received multiple favorable developments [1]
港股异动 | 药捷安康-B(02617)再涨超60% 入通后累涨近10倍 北水近两日累计加仓超3亿港元